# Callio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/callio-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.calliotx.com
- Total disclosed funding: $187M
- Latest round: Series A (Mar 3, 2025)
- Investors on record: 10

## About

Callio Therapeutics specializes in advancing innovative biopharmaceutical solutions, focusing on the development of therapies for serious diseases, particularly in the oncology space. Founded in 2025 by CEO Piers Ingram and CSO Jerome Boyd-Kirkup, Callio Therapeutics is focused on developing groundbreaking biopharmaceutical therapies. The company is headquartered in Seattle, US. In March 2025, Callio Therapeutics raised USD 187 mn in Series A funding led by Frazier Healthcare Partners, with participation from BB Pureos Bioventures, Clavystbio, EDBI, Jeito Capital, Norwest Venture Partners, Novo Holdings, Omega Funds, Platanus Ventures, and SEEDS Capital. The funding will be utilized for their research and development initiatives. The company was founded by individuals with extensive experience in the biopharmaceutical industry, although specific names are not disclosed. Callio Therapeutics specializes in delivering innovative solutions within the biopharmaceutical sector, focusing on therapies designed to treat serious diseases, particularly in oncology. Their core offerings include a pipeline of drug candidates aimed at addressing significant unmet medical needs, enhancing treatment efficiency and effectiveness. The company targets markets in North America and Europe, establishing partnerships with both healthcare providers and research institutions to facilitate the development and distribution of their therapies. Callio Therapeutics generates revenue primarily through partnerships and collaborations in the biopharmaceutical sector, including agreements with research institutions and healthcare organizations. The funding from recent investment rounds supports their operations, allowing for dedicated research efforts while maintaining relationships with partners to drive revenue through future therapies and clinical developments. Callio Therapeutics plans to develop and launch new therapies within its pipeline, specifically targeting oncology-related treatments set for clinical trial phases in the next 12 to 18 months. In addition, the company aims to expand its presence into European markets by 2026. The recent funding of USD 187 mn raised in March 2025 will be pivotal in supporting their research and development initiatives, enhancing their capabilities to bring new therapeutic solutions to market.

## Funding rounds

- Series A, Mar 3, 2025, $187M — Frazier Healthcare Partners, Norwest Venture Partners, Novo Holdings, SG Growth Capital, Omega Funds, SEEDS Capital, Jeito Capital, Pureos Bioventures, Platanus Ventures, ClavystBio

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A
- Novo Holdings — Series A
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A
- Platanus Ventures (https://capitalatlas.ai/funds/platanus-ventures) — Series A
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Series A